Skip to main content

Table 1 Failures of phase III clinical trials of immunotherapy for GBM

From: Immunotherapy for glioblastoma: the promise of combination strategies

Trial Treatment Outcome Reference
CheckMate 143 phase III (NCT02017717) anti-PD-1 (nivolumab) vs anti-VEGF (bevacizumab) Primary endpoint not reached
↔ No improvement of mOS with anti-PD-1 (9.8 months) vs anti-VEGF (10 months)
Reardon et al., (2020) [110]
CheckMate 498 phase III (NCT02617589) anti-PD-1 (nivolumab) + RT vs TMZ + RT Primary endpoint not reached
↔ No improvement of mOS with anti-PD-1 + RT (13.4 months) vs control treatment (14.9 months)
BMS press release; ClinicalTrials.gov
CheckMate 548 phase III (NCT02667587) anti-PD-1 (nivolumab) + SOC vs placebo + SOC Primary endpoint not reached
Data not yet released
BMS press release
ACT IV phase III (NCT01480479) Peptide vaccine targeting EGFRvIII (rindopepimut) + TMZ vs placebo + TMZ Primary endpoint not reached
↔ No improvement of mOS with rindopepimut (20.1 months) vs control group (20.0 months)
Weller et al., (2017) [111]
NCT00045968 phase III Dendritic cell vaccine (DCVax®-L) + SOC vs placebo + SOC Put on hold
For unidentified reasons
Liau et al., (2018) [112]; ClinicalTrials.gov